Generic Name and Formulations:
Alprostadil (in alfadex inclusion complex) 10mcg, 20mcg, 40mcg; per cartridge; pwd for intracavernous inj after reconstitution.
Indications for EDEX:
Inject over 5–10 seconds into the lateral aspect of the proximal third of the penis, avoid visible veins; rotate injection side and site. Determine optimum dose in office. If no response occurs, may give next higher dose in 1 hour. If response occurs, must wait 24 hours before next dose. Vasculogenic, psychogenic, or mixed etiology: initially 2.5mcg. If partial response to initial dose, may give 2nd dose of 5mcg and then may increase by increments of 5–10mcg until desired response achieved. If no response to initial dose, may give 2nd dose of 7.5mcg and then may increase by increments of 5–10mcg until desired response achieved. Neurogenic etiology: initially 1.25mcg. May give 2nd dose of 2.5mcg, and 3rd dose of 5mcg, and then may increase by increments of 5mcg until desired response achieved. Max: 40mcg and 3 self-injections per week; allow at least 24 hours between doses. Reduce dose if erection lasts over 1 hour.
Predisposition to priapism. Fibrotic conditions of the penis (eg, cavernosal fibrosis, Peyronie's disease). Penile implants.
Treat priapism immediately. Reevaluate every 3 months. Discontinue if penile fibrosis occurs. Preexisting cardiovascular disease. Renal impairment. Elderly. Pregnancy, nursing mothers: not indicated.
Concomitant vasoactive agents: not recommended. Caution with concomitant heparin.
Penile pain, priapism, inj site reactions, penile angulation or fibrosis, hypertension, headache, dizziness, upper respiratory infections, others.
2-cartridge pack (w. 1 inj device & supplies)—1; 6-cartridge pack (w. 1 inj device & supplies)—1
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC